{"product_id":"collegiumpharma-pestle-analysis","title":"Collegium Pharmaceutical PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how regulatory pressures, opioid litigation risk, and shifting reimbursement dynamics are shaping Collegium Pharmaceutical’s strategic outlook—our concise PESTLE highlights the external forces investors and managers must watch. Purchase the full PESTLE to access actionable, sector-specific intelligence and downloadable templates that speed decision-making and strengthen your investment thesis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal regulation of opioid prescriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFederal oversight of opioid prescriptions will continue shaping prescribing volumes and physician behavior through 2025, with CDC and HHS guidance contributing to a 23% decline in opioid MME per capita from 2019–2023 that affects demand for Collegium’s pain portfolio.\u003c\/p\u003e \n\u003cp\u003eLegislative efforts, including federal funding increases (HHS opioid budget rose to about $7.3 billion in FY2024), tighten marketing practices for specialty firms and raise compliance costs for Collegium.\u003c\/p\u003e\n\u003cp\u003eAgencies balance chronic pain relief and misuse prevention, maintaining prior authorization trends that can delay prescriptions and pressure revenues tied to opioid products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Medicaid reimbursement policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in Medicare and Medicaid reimbursement materially affect Collegium’s pricing and access for Xtampza ER and Nucynta; CMS drug spending reached $378 billion in 2023, increasing leverage in price negotiations that can compress margins for specialty opioids.\u003c\/p\u003e\n\u003cp\u003eOngoing political pressure to lower senior drug costs, including Medicare Part D reforms in 2024-25, risks formulary exclusions or deeper rebates that could reduce net revenue for branded products.\u003c\/p\u003e\n\u003cp\u003ePolicymakers shifting to value-based care and prioritizing abuse-deterrent formulations could favor Xtampza ER—opioid-related hospitalizations cost Medicare ~$35 billion annually—potentially improving coverage if payers adopt outcomes-linked reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEA production quotas for controlled substances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe DEA sets annual aggregate production quotas for Schedule II substances that feed Collegium Pharmaceutical’s pain portfolio; in 2024 the DEA cut certain opioid quotas by about 10–20%, and further policy shifts could reduce availability, risking supply constraints and lost sales—Collegium reported net product sales of $184.5M in 2024, so quota-driven shortages could materially impact revenue; constant alignment with federal drug control policy is required to mitigate these risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLobbying and advocacy for pain management standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe political debate over pain management pits patient advocacy groups against anti-addiction activists, forcing Collegium to lobby to protect access for chronic pain sufferers while addressing misuse concerns; in 2024 U.S. opioid prescribing fell 12% vs 2019, intensifying scrutiny.\u003c\/p\u003e\n\u003cp\u003eShifts favoring non-opioid therapies have led to increased federal funding—NIH awarded $1.1B for pain research in FY2024—while support for abuse-deterrent formulations boosts market potential for Collegium’s Xtampza ER.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy tensions require active lobbying to preserve patient access\u003c\/li\u003e\n\u003cli\u003e12% drop in opioid prescribing since 2019 increases scrutiny\u003c\/li\u003e\n\u003cli\u003e$1.1B NIH pain research funding in FY2024 favors non-opioid development\u003c\/li\u003e\n\u003cli\u003ePolicy support for abuse-deterrent tech strengthens market for Xtampza ER\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-level prescription monitoring programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState PDMPs mandate checks that have contributed to a decline in opioid prescriptions; U.S. opioid prescriptions fell ~44% from 2012 to 2022, and mandatory PDMP use in 38 states (as of 2024) constrains volume for companies like Collegium.\u003c\/p\u003e\n\u003cp\u003eMandatory PDMP checks correlate with reduced opioid dispensing—studies show 8–12% decreases post-implementation—forcing Collegium to protect market share via non-opioid portfolios and targeted education.\u003c\/p\u003e\n\u003cp\u003eVariation across states—some with stricter PDMP enforcement and others with expanding mandates—requires localized commercial strategies and focused government relations to navigate reimbursement and prescribing behavior.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e38 states had mandatory PDMP checks by 2024\u003c\/li\u003e\n\u003cli\u003eU.S. opioid prescriptions down ~44% (2012–2022)\u003c\/li\u003e\n\u003cli\u003ePDMPs associated with ~8–12% reduction in dispensing\u003c\/li\u003e\n\u003cli\u003eLocalized gov’t relations and commercial tactics needed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy Cuts Slash Opioid Supply, Pressuring Collegium While Boosting Xtampza ER\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal and state opioid policies—from DEA quota cuts (10–20% in 2024) and 38 states' mandatory PDMPs to Medicare\/Medicaid pricing reforms and $7.3B HHS opioid funding in FY2024—have reduced U.S. opioid MME per capita 23% (2019–2023) and prescriptions ~12% (2019–2024), pressuring Collegium’s opioid revenue while creating opportunities for abuse-deterrent Xtampza ER.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEA quota change (2024)\u003c\/td\u003e\n\u003ctd\u003e-10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates with PDMP mandates (2024)\u003c\/td\u003e\n\u003ctd\u003e38\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid MME per capita (2019–2023)\u003c\/td\u003e\n\u003ctd\u003e-23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHHS opioid budget (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$7.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Collegium Pharmaceutical across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven trends and forward-looking insights tailored for executives, investors, and strategists to identify risks, opportunities, and scenario-based actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise PESTLE summary tailored to Collegium Pharmaceutical that highlights regulatory, market, and technological risks and opportunities for quick use in presentations or team planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of inflation on manufacturing and distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 has raised specialty pharma input costs—API and excipient prices up ~6–9% YoY and US labor costs for pharmaceutical manufacturing rising ~4–5% in 2024—raising COGS pressure for Collegium Pharmaceutical; inability to fully pass increases to payers could compress margins (median gross margin for specialty pharma ~60%, a 2–4 percentage-point hit would be material). Efficient supply-chain actions (inventory turns, contract logistics) are therefore critical to preserve financial stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket competition from generic alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical faces economic pressure as generic entrants undercut prices—US opioid generics grew 12% in volume in 2024, compressing margins for branded abuse-deterrent products like Xtampza ER, which generated $227m revenue in 2023 but saw growth slow in 2024. Defending share requires costly marketing, physician education and real‑world evidence studies; Collegium spent an estimated $50–70m annually on commercialization in recent years. Patent expirations and loss of exclusivity pose major revenue risk: key patents for Xtampza ER run into the late 2020s, and generic substitution could cut revenues by 30–60% within two years of entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare payer landscape and formulary positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsolidation among PBMs and insurers has concentrated buying power—top three PBMs covered ~80% of US prescriptions in 2024—forcing Collegium to negotiate access with few large gatekeepers.\u003c\/p\u003e\n\u003cp\u003eFavorable formulary placement increasingly requires rebates; industry rebate levels averaged 20–40% in 2023–24, compressing Collegium’s net prices and margins.\u003c\/p\u003e\n\u003cp\u003eCollegium’s economic success hinges on demonstrating cost-effectiveness and real-world outcomes to secure placement and mitigate rebate-driven revenue erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and capital allocation strategies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe late-2025 Fed funds rate at about 5.25–5.50% raises Collegium Pharmaceutical’s borrowing costs, tightening funding for M\u0026amp;A and potentially increasing interest expense on variable-rate debt, pressuring free cash flow.\u003c\/p\u003e\n\u003cp\u003eHigh rates likely shift management toward organic growth and debt reduction over aggressive R\u0026amp;D or acquisitions; investors will scrutinize capital allocation between reinvestment in the CNS pipeline, dividends, and buybacks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFed funds ~5.25–5.50% (late 2025)\u003c\/li\u003e\n\u003cli\u003eHigher borrowing costs reduce M\u0026amp;A firepower and raise interest expense\u003c\/li\u003e\n\u003cli\u003ePriority shift: organic growth and debt paydown\u003c\/li\u003e\n\u003cli\u003eInvestor focus: pipeline reinvestment vs dividends\/share buybacks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer spending power and out-of-pocket costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic downturns and wage stagnation reduce disposable income, lowering adherence to branded pain meds; 2024 US real median household income fell 1.0% year-over-year, amplifying switch to generics.\u003c\/p\u003e\n\u003cp\u003eRising enrollment in high-deductible health plans—over 40% of covered workers in 2024—pushes patients away from costly specialty therapies, cutting prescription volumes.\u003c\/p\u003e\n\u003cp\u003eCollegium may need expanded patient-assistance programs; in 2023 pharma PAPs covered \u0026gt;10% of prescriptions in some specialty categories to maintain access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncome pressure → lower branded adherence\u003c\/li\u003e\n\u003cli\u003e40%+ HDHP penetration reduces specialty uptake\u003c\/li\u003e\n\u003cli\u003ePAPs necessary; specialty PAPs covered \u0026gt;10% prescriptions (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs, PBM squeeze and tighter rates squeeze Collegium’s margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation, rising API\/labor costs (+6–9% APis, +4–5% labor 2024), higher rebates (20–40%), PBM consolidation (top3 ~80% prescriptions 2024), generic pressure (opioid generics +12% vol 2024) and Fed funds ~5.25–5.50% (late‑2025) compress Collegium’s margins, raise borrowing costs and force focus on cost control, PAPs and evidence to defend formulary access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/labor inflation\u003c\/td\u003e\n\u003ctd\u003e+6–9% \/ +4–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebates\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM share (top3)\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid generics vol\u003c\/td\u003e\n\u003ctd\u003e+12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (late‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Collegium Pharmaceutical PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e \u003cp\u003eNo placeholders or teasers: the content, layout, and detail visible in the preview are identical to the downloadable file you’ll get immediately upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751273345401,"sku":"collegiumpharma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/collegiumpharma-pestle-analysis.png?v=1772229597","url":"https:\/\/matrixbcg.com\/products\/collegiumpharma-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}